By Jessica Langholtz
Published: May 22, 2012 11:35 am
According to a recent Phase 1/2 study conducted in Europe, the combination of Velcade and cytarabine may be effective and safe in higher-risk myelodysplastic syndromes patients who have not been previously treated.
In addition, the combination showed activity in patients with unfavorable chromosomal abnormalities. Specifically, 13 percent of these patients responded, which the investigators describe as notable, since no patients with these types of chromosomal abnormalities responded in previous studies testing cytarabine alone.
For more information, see the study in the British Journal of Haematology (abstract).
Married, father of three daughters; now 46; diagnosed w/ Major form MDS 6/18/2013; had low counts across the board; Multiple chromosome abnormalities; Finished 2nd round Dacogen 9/13; SCT - Oct. 31, 2013; Sibling match 10/10
; 5.5% blasts down to 3%, now 1% (post BMT)